Study on protective effect and mechanism of Modified Yupingfeng nasal spray on nasal mucosal injury in AR model rats

XI Yuan; HE Xinning; LIU Yuyin; ZHANG Na; LIU Ting; LIANG Fangqi; TIAN Li

doi:10.6039/j.issn.1001-0408.2023.10.10

您当前的位置：

首页 >

文章列表页 >

Study on protective effect and mechanism of Modified Yupingfeng nasal spray on nasal mucosal injury in AR model rats

更新时间：2023-05-25

- Study on protective effect and mechanism of Modified Yupingfeng nasal spray on nasal mucosal injury in AR model rats
- ZHONGGUO YAOFANG Vol. 34, Issue 10, Pages: 1204-1210(2023)
- 作者机构：
  
  成都中医药大学附属医院耳鼻喉科，成都　610032
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.10.10
  CLC： R965;R276.1
- Published：30 May 2023，
  
  Received：21 September 2022，
  
  Revised：13 February 2023，
扫描看全文
习媛,贺心宁,刘玉崟等.玉屏风加味鼻喷剂对AR模型大鼠鼻黏膜损伤的保护作用及机制研究 ^Δ[J].中国药房,2023,34(10):1204-1210.

XI Yuan,HE Xinning,LIU Yuyin,et al.Study on protective effect and mechanism of Modified Yupingfeng nasal spray on nasal mucosal injury in AR model rats[J].ZHONGGUO YAOFANG,2023,34(10):1204-1210.
习媛,贺心宁,刘玉崟等.玉屏风加味鼻喷剂对AR模型大鼠鼻黏膜损伤的保护作用及机制研究 ^Δ[J].中国药房,2023,34(10):1204-1210. DOI： 10.6039/j.issn.1001-0408.2023.10.10.

XI Yuan,HE Xinning,LIU Yuyin,et al.Study on protective effect and mechanism of Modified Yupingfeng nasal spray on nasal mucosal injury in AR model rats[J].ZHONGGUO YAOFANG,2023,34(10):1204-1210. DOI： 10.6039/j.issn.1001-0408.2023.10.10.

摘要

目的

研究玉屏风加味鼻喷剂（YPF+）对变应性鼻炎（AR）模型大鼠鼻黏膜损伤的保护作用及潜在机制。

方法

以卵清蛋白（OVA）诱导建立大鼠AR模型。将造模成功的大鼠随机分为模型组、YPF+组（每侧50 μg，每天2次）和阳性对照组（糠酸莫米松鼻喷雾剂，每侧50 μg，每天1次），并设空白组，每组10只。各药物组大鼠给予相应药物，空白组和模型组大鼠给予等量生理盐水，连续4周。末次给药结束30 min后，记录各组大鼠的行为评分，观察其鼻黏膜组织的病理改变；检测其鼻黏膜组织中活性氧（ROS）水平，核苷酸结合寡聚化结构域样受体蛋白3（NLRP3）、胱天蛋白酶1（caspase-1）、gasdermin D（GSDMD）蛋白及mRNA的表达水平，以及血清中白细胞介素1β（IL-1β）、IL-18含量。

结果

与空白组比较，模型组大鼠鼻黏膜组织结构紊乱，炎症细胞浸润严重，并可见固有层血管扩张；其行为学评分和病理评分，鼻黏膜组织中ROS水平，NLRP3、caspase-1、GSDMD蛋白及其mRNA的表达水平，以及血清IL-1β、IL-18含量均显著升高（

＜0.05）。与模型组比较，各药物组大鼠鼻黏膜损伤症状均有不同程度改善，上述指标均显著降低（

＜0.05）。

结论

YPF+可改善大鼠鼻黏膜损伤，减轻其喷嚏、鼻痒、鼻涕等AR症状，这种作用可能与其减少鼻黏膜ROS产生、下调NLRP3/caspase-1/GSDMD通路有关。

Abstract

OBJECTIVE

To study protective effect and potential mechanism of Modified yupingfeng nasal spray （YPF+） on nasal mucosal injury in allergic rhinitis （AR） model rats.

METHODS

AR model was induced by ovalbumin （OVA） and randomly divided into model group， YPF+group （50 µg/side，twice a day）， positive control group （Mometasone furoate aqueous nasal spray， 50 µg/side，once a day）； the blank group was set up， with 10 rats in each group. Administration groups were given relevant medicine， and blank group and model group were given equivalent normal saline for consecutive 4 weeks. Thirty minutes after last medication， the behavioral scores of rats were recorded， and the pathological changes of their nasal mucosa tissue were observed. The level of reactive oxygen species （ROS） in nasal mucosa tissue was detected. The protein and mRNA expressions of nucleotide-binding oligomerization domain-like receptor protein 3 （NLRP3），caspase-1，gasdermin D （GSDMD） were detected； the contents of interleukin-1β （IL-1β） and IL-18 in serum were also determined.

RESULTS

Compared with blank group， in model group， the nasal mucosa tissue structure was disordered， inflammatory cells infiltrated seriously， and lamina propria vascular dilation was visible； its behavioral score and pathological score， the level of ROS， protein and mRNA expressions of NLRP3， caspase-1 and GSDMD， serum contents of IL-1β and IL-18 in nasal mucosa tissue were increased significantly （

＜0.05）. Compared with model group， the symptoms of nasal mucosal injury in rats of each drug group were improved to varying degrees， and the above indicators were significantly reduced （

＜0.05）.

CONCLUSIONS

YPF+ may improve nasal mucosal injury of rats， relieve AR symptoms such as sneezing， itchy nose， runny nose， the mechanism of which may be associated with reducing the production of ROS in nasal mucosa and downregulating NLRP3/caspase-1/GSDMD pathway.

关键词

玉屏风加味鼻喷剂变应性鼻炎NLRP3/caspase-1/GSDMD通路活性氧

Keywords

allergic rhinitisNLRP3/caspase-1/GSDMD pathwayreactive oxygen species

references

中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组，中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 中国变应性鼻炎诊断和治疗指南：2022年，修订版[J]. 中华耳鼻咽喉头颈外科杂志，2022，57（2）：106-129.

ZHANG Y，ZHANG L. Increasing prevalence of allergic rhinitis in China[J]. Allergy Asthma Immunol Res，2019，11（2）：156-169.

魏亚宁，仇惠莺. NLRP3炎症小体活化促进上皮细胞焦亡诱导变应性鼻炎[J]. 免疫学杂志，2021，37（2）：140-144.

ZHANG Y L，SONG Y L，WANG C Y，et al. Panax notoginseng saponin R1 attenuates allergic rhinitis through AMPK/Drp1 mediated mitochondrial fission[J]. Biochem Pharmacol，2022，202：115106.

YANG Z X，LIANG C Q，WANG T Y，et al. NLRP3 inflammasome activation promotes the development of al-lergic rhinitis via epithelium pyroptosis[J]. Biochem Biophys Res Commun，2020，522（1）：61-67.

刘真，宋西成. 细胞焦亡在变应性鼻炎中的作用机制及研究进展[J]. 山东大学耳鼻喉眼学报，2022，36（3）：123-129.

AKDIS C A. Does the epithelial barrier hypothesis explain the increase in allergy，autoimmunity and other chronic conditions?[J]. Nat Rev Immunol，2021，21（11）：739-751.

SONG J L. Effects of Yu-Ping-Feng granules combined with loratadine tablets on treatment efficacy and immune factor levels in allergic rhinitis patients[J]. Am J Transl Res，2021，13（5）：5192-5199.

LIU B，HUANG X M，XIA L N，et al. Effects of Yupingfeng nasal drops on serum cytokines，histopathology and eosinophil cationic protein in nasal mucosa of rats with allergic rhinitis[J]. Pak J Pharm Sci，2021，34（4）：1351-1358.

慕德宏，刘慧霞，李东棋，等. 克敏芪丹鼻喷剂对气虚血瘀证变应性鼻炎大鼠血清IL-4、PAF的影响[J]. 中国免疫学杂志，2020，36（24）：2981-2985.

HUANG X，LIU B，TIAN L. Intranasal concentration gradient of Yupingfeng promotes induction of microRNA-21 by PTEN to reverse activation of OVA mimicking allergic rhinitis[J]. Revue Française d’Allergologie，2019，59（7）：481-486.

WANG D，TIAN T，LIU B，et al. Mechanism of modified Yupingfeng naristillae in protecting the nasal mucosal epithelial barrier during allergic rhinitis[J]. Revue Française d’Allergologie，2021，61（3）：145-152.

苗明三，项丽玲，苗艳艳. 变应性鼻炎动物模型制备规范：草案[J]. 中草药，2018，49（1）：50-57.

李佳锋，徐佳俊，高翔，等. 变应性鼻炎大鼠动物模型的建立及评价[J]. 四川解剖学杂志，2016，24（1）：4-6，11.

黄柳明. 一种规范化的苏木素染色方法[J]. 中国当代医药，2009，16（16）：81-82.

吉晓滨，杜洪，臧林泉，等. 豚鼠变应性鼻炎模型鼻黏膜的病理改变[J]. 山东大学耳鼻喉眼学报，2007，21（4）：312-315.

杨钦泰，陈建军，谭国林，等. 鼻用糖皮质激素治疗变应性鼻炎专家共识：2021，上海[J]. 中国耳鼻咽喉颅底外科杂志，2021，27（4）：365-371.

刘莉莉，刘大新，刘锦峰，等. 中医药临床优势病种探讨：变应性鼻炎[J]. 中国实验方剂学杂志，2023，29（2）：203-211.

ZHOU H Q，ZHANG W，QIN D X，et al. Activation of NLRP3 inflammasome contributes to the inflammatory response to allergic rhinitis via macrophage pyroptosis[J]. Int Immunopharmacol，2022，110：109012.

WAN H J，SU H X，WU Y Y，et al. Expression and significance of NLRP3 inflammasome and its downstream factors IL-1β/IL-18 in rat model of allergic rhinitis[J]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi，2015，50（2）：145-150.

YU X F，WANG M，ZHAO H，et al. Targeting a novel hsa_circ_0000520/miR-556-5p/NLRP3 pathway-mediated cell pyroptosis and inflammation attenuates ovalbumin（OVA）-induced allergic rhinitis（AR）in mice models[J]. Inflamm Res，2021，70（6）：719-729.

SHI Q P，LEI Z W，CHENG G，et al. Mitochondrial ROS activate interleukin-1β expression in allergic rhinitis[J]. Oncol Lett，2018，16（3）：3193-3200.

LI Y，OUYANG Y H，JIAO J，et al. Exposure to environmental black carbon exacerbates nasal epithelial inflammation via the reactive oxygen species（ROS）-nucleotide-binding，oligomerization domain-like receptor family，pyrin domain containing 3（NLRP3）-caspase-1-interleukin 1β（IL-1β）pathway[J]. Int Forum Allergy Rhinol，2021，11（4）：773-783.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on the effects of 17-hydroxy-jolkinolide B on the proliferation and apoptosis of human triple-negative breast cancer cells

芹黄素对香烟提取物诱导人支气管上皮NCI-H292细胞黏蛋白5AC高表达的抑制作用

齐墩果酸对氧化损伤人脐静脉内皮细胞线粒体中一氧化氮合酶的调控作用

扇贝糖胺聚糖对OX-LDL诱导血管内皮细胞氧化应激损伤的抑制作用机制研究

天然产物通过增加活性氧抗肿瘤的研究进展

Related Author

HAN Cuicui

YANG Dongxing

PAN Siwen

LIN Yu

BAO Yanan

XU Lei

WU Siming

GONG Fei

Related Institution

College of Pharmacy， Qiqihar Medical University

Dept. of Vascular Surgery， the First Hospital of Qiqihar

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰